NDC 70771-1105-01 - CHOLESTYRAMINE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70771-1105
- Requested NDC
- 70771-1105-01
- Package NDCs from labels
- 70771-1105-1, 70771-1105-2, 70771-1105-01
- Manufacturer
- Zydus Lifesciences Limited
- Effective date
- 2026-04-28
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| CHOLESTYRAMINE - Zydus Lifesciences Limited | Zydus Lifesciences Limited | 2026-04-28 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70771-1105-1 | CHOLESTYRAMINE | 378 g in 1 CAN | POWDER, FOR SUSPENSION | 378 | 5 | |
| 70771-1105-2 | CHOLESTYRAMINE | 60 in 1 CARTON | POWDER, FOR SUSPENSION | 60 | 5 | |
| 70771-1105-2 | CHOLESTYRAMINE | 9 g in 1 POUCH | POWDER, FOR SUSPENSION | 9 | 5 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 70771-1105 | CHOLESTYRAMINE POWDER, FOR SUSPENSION [ZYDUS LIFESCIENCES LIMITED] | 4 | Current NDC, Legacy NDC, 3 package rows | 20240110_a86715e3-741f-47c6-9682-1413f0f8ff0c.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cholestyramine | CHOLESTYRAMINE | TAGI Pharma, Inc. | 06261db5-1435-4b91-8b54-71bfcfb1368c | 2025-04-17 | Adverse reactions | 848943 4B33BGI082 |
| Cholestyramine Light | CHOLESTYRAMINE | TAGI Pharma, Inc. | eb85a2c8-cdc3-48bb-844d-e220ae3701a0 | 2025-04-17 | Warnings, Adverse reactions | 4B33BGI082 |
| Bio Co Enzyme Phase | ACONITICUM ACIDUM, CIS-, ADENOSINUM TRIPHOSPHORICUM DINATRUM, ADRENALINUM, , ALPHA-KETOGLUTARICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, ASCORBICUM ACIDUM, BARIUM OXALSUCCINICUM, BETA VULGARIS, CERIUM OXALICUM, CITRICUM ACIDUM, CYSTEINUM, FUMARICUM ACIDUM, HEPAR SULPHURIS CALCAREUM, MAGNESIUM OROTICUM DIHYDRICUM, MALICUM ACIDUM, MANGANUM PHOSPHORICUM, NADIDUM, NATRUM OXALACETICUM, NATRUM PYRUVICUM, NICOTINAMIDUM, PANTOTHENIC ACID, PROTEUS (MORGANI), PULSATILLA (PRATENSIS), PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM, | Deseret Biologicals, Inc. | 6edee6eb-0ec9-4d2a-9dc9-dc2a6503a6db | 2025-04-08 | Warnings | XF417D3PSL |
| Cholestyramine | CHOLESTYRAMINE | Precision Dose, Inc. | 8c7fc9c8-318c-42de-a736-c439047d8af8 | 2025-03-12 | Adverse reactions | 848943 4B33BGI082 |
| Alcostat | TARAXACUM OFFICINALE, AVENA SATIVA, PASSIFLORA INCARNATA, AURUM METALLICUM, CAPSICUM ANNUUM, CHELIDONIUM MAJUS, LACHESIS MUTUS, LYCOPODIUM CLAVATUM, NOX VOMICA, QUERCUS GLANDIUM SPIRITUS, SULPHURICUM ACIDUM, ETHYLICUM, CARCINOSIN, SACCHARUM OFFICINALE | Energique, Inc. | 77daea02-3c32-4ba3-a7a8-af79b13ddc06 | 2025-02-27 | Warnings | C151H8M554 |
| Cholestyramine | CHOLESTYRAMINE | Macleods Pharmaceuticals Limited | c41529f1-16d2-4ca3-91eb-f809571f5ae3 | 2025-01-30 | Warnings, Adverse reactions | 4B33BGI082 |
| Anise Pyrite | ANISE PYRITE | Uriel Pharmacy Inc. | a03cdeb0-8347-40cc-8d17-5510d99575c7 | 2025-01-22 | Warnings | C151H8M554 |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID MONOHYDRATE | AvPAK | fe070e2e-3e72-fb84-e053-6294a90afd88 | 2025-01-09 | Adverse reactions | XF417D3PSL |
| A-6 | LEMON, ORANGE, AND GRAPEFRUIT | DNA Labs, Inc. | b5cf44e0-09cd-48ef-9132-cf6e93bdd429 | 2025-01-09 | Warnings | 5EVU04N5QU |
| A-5 | SUCROSE | DNA Labs, Inc. | 8e63f697-26c1-4518-acd3-5ea72cfa27f7 | 2025-01-09 | Warnings | C151H8M554 |
| Gut Brain Spectrum | ABROTANUM (ARTEMISIA ABROTANUM), AETHUSA CYNAPIUM, BAPTISIA TINCTORIA, CICUTA VIROSA, CUPRUM METALLICUM, MEZEREUM, BUFO RANA, LAC MATERNA HUMANUM, SACCHARUM OFFICINALE, SEROTONIN (HYDROCHLORIDE), ALUMINA, CALCAREA PHOSPHORICA, CANDIDA ALBICANS, CARCINOSIN, LAC CANINUM, MERCURIUS SOLUBILIS, NATRUM MURIATICUM, PROPIONIC ACID, SULPHUR, THUJA OCCIDENTALIS, FORMALINUM, MORBILLINUM | Energique, Inc. | adfee6ce-05b0-4955-bf5f-9612b8db4c78 | 2024-12-26 | Warnings | C151H8M554 |
| Equaline Effervescent Antacid and Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | United Natural Foods, Inc. dba UNFI | 739237a5-cc62-8ad6-e053-2991aa0a91f8 | 2024-12-17 | Warnings | XF417D3PSL |
| Alka-Seltzer Heartburn and Pain | ANHYDROUS CITRIC ACID, ASPIRIN, AND SODIUM BICARBONATE | Bayer HealthCare LLC. | 2928e140-c868-5bf5-e063-6394a90ab024 | 2024-12-13 | Warnings | XF417D3PSL |
| Rite Aid Antacid and Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Rite Aid | b4797380-9cef-d640-e053-2a95a90a0665 | 2024-12-11 | Warnings | XF417D3PSL |
| Top Value Effervescent Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICAROBONATE | Tower Laboratories Ltd | 44babed8-cf38-1c12-e054-00144ff8d46c | 2024-12-11 | Warnings, Adverse reactions | XF417D3PSL |
| Best Choice Effervescent Antacid Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Valu Merchandisers Company | b5e2300a-b77b-53cc-e053-2a95a90a7a6e | 2024-12-11 | Warnings | XF417D3PSL |
| CVS Health Extra Strength Antacid and Pain Reliever | ASPIRIN, ANHYDROUS CITRIC ACID, SODIUM BICARBONATE | CVS Pharmacy | afe9e755-18ba-305f-e053-2995a90aa8d0 | 2024-11-14 | Warnings | XF417D3PSL |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID MONOHYDRATE | Pharmaceutical Associates, Inc. | 63201a61-6ac5-41ae-8b2d-ff0d3a8ddfd5 | 2024-11-13 | Adverse reactions | XF417D3PSL |
| Walgreens Effervescent Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Walgreens | 667418fc-a3ab-cbc7-e053-2a91aa0a2023 | 2024-11-13 | Warnings | XF417D3PSL |
| Up and Up Antacid and Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Target Corporation | a72eef45-b985-638a-e053-2995a90aa20a | 2024-11-13 | Warnings | XF417D3PSL |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.